Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
Status:
RECRUITING
Trial end date:
2029-07-31
Target enrollment:
Participant gender:
Summary
This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.
Phase:
PHASE4
Details
Lead Sponsor:
Tulane University
Collaborators:
Louisiana State University Health Sciences Center in New Orleans Segal Trials Healthcare Clinical Data, Inc University of Alabama at Birmingham